In recent years, mesenchymal stem cells (MSCs) have emerged as a potential therapy for the treatment of diabetic nephropathy (DN). DN is a leading cause of renal failure and is associated with a high risk of mortality. Despite advances in the management of diabetes, the incidence of DN is increasing. There is therefore a need for new and effective treatments for this condition. MSCs are a type of adult stem cell that can be isolated from a variety of tissues, including the bone marrow, adipose tissue, and umbilical cord. MSCs have the ability to self-renew and to differentiate into a variety of cell types, including osteoblasts, chondrocytes, and adipocytes. MSCs have a number of properties that make them attractive as a treatment for DN. Firstly, MSCs are immunosuppressive and can therefore modulate the autoimmune response in DN. Secondly, MSCs can secrete a number of factors that have anti-inflammatory and anti-fibrotic effects. Finally, MSCs can promote angiogenesis and reduce oxidative stress. A number of studies have shown that MSCs can improve the renal function in animal models of DN. For example, one study showed that the infusion of MSCs improved renal function and reduced the progression of DN in rats. Another study showed that the transplantation of MSCs reduced the levels of albuminuria, a marker of renal damage, in rats with DN. Clinical trials are currently underway to assess the safety and efficacy of MSCs in the treatment of DN. The results of these trials will be important in determining whether MSCs can be used as a treatment for this condition.
"Mesenchymal Stem Cells: An Overview of Their Potential in ... - NCBI." 16 Mar. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990550/. Accessed 24 Oct. 2022.
"The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy - PMC." 7 Jun. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216044/. Accessed 24 Oct. 2022.
"Administration of mesenchymal stem cells in diabetic kidney disease." 7 Jan. 2021, https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-02108-5. Accessed 24 Oct. 2022.
The information below is the recommended stem cell therapy protocol for this condition
|Route of Administration